1Anastaia P,Joanna ML,Virginia C,et al. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associat- ed ophthalmopathy. Br J Ophthalmol, 2000,84(5) : 517-522.
4Galuska L,I.eovey A,Szucs-Farkas Z,et al. SPECT using 9I'c- DTPA for the assessment of disease activity in Graves" ophthal- mopathy: a comparison with the results from MRI. Nucl Med Commun, 2002,23(12) : 1211-1216.
6Galuska L,Leovey A,Szucs-farkas Z,et al. Imaging of disease ac- tivity in Graves' orbitopathy with different methods: comparison of q'c-DTPA and Yc-depreotidesingle photon emission to- mography,magnetic resonance imaging and clinical activity scores. Nucl Med Commun,2005,26 (5):407-414.
6Pappa A,Lawson JM,Calder V,et al.T cells and fibroblasts in affected extraoculas muscles in early and late thyroid associated ophthalmopathy.Br J Ophthalmol,2000,84(5):517-522.
7Moncayo R,Baldissera I,Decristoforo C,et al.Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatestatin analog 11In-octreotide.Thyroid,1997,7(1):21-29.
8Burggasser G,Hurtl I,Hauff W,et al.Orbital seintigraphy with the somatostatin receptor tracer 99Tc-P829 in patients with Graves' disease.J Nucl Med,2003,44(10):1547-1555.
9Kainz H,Bale R,Donnemiller E,et al.Image fusion analysis of 99MTc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy:the importance of the lacrimal gland.Eur J Nucl Med Mol Imaging,2003,30(8):1155-1159.
10Krassas GE,Doumas A,Kaltsas T,et al.Somatestatin receptor scintigraphy before and after treatment with somatestatin analogues in patients with thyroid eye disease.Thyroid,1999,9(1):47-52.
